Form 4: CYTOKINETICS CFO Lee Sung Reports Stock Transactions

CYTOKINETICS' EVP and CFO, Sung Lee, reported the acquisition of performance shares and a sale for tax withholding purposes.

Summary

• Sung Lee, Executive Vice President and Chief Financial Officer of CYTOKINETICS INC, reported transactions involving the company's common stock.
• On December 22, 2025, Lee acquired 2,152 shares of common stock as performance shares, which remain subject to a 1-year time vesting requirement.
• On the same date, Lee acquired an additional 2,152 shares of common stock as performance shares, which vested immediately.
• Also on December 22, 2025, 805 shares were disposed of at a price of $62.72 per share to cover tax withholding obligations upon the vesting of performance shares.
• Following these transactions, Sung Lee directly beneficially owns 71,416 shares of CYTOKINETICS INC common stock.

Sentiment

Score: 6

Explanation: The filing is largely neutral, reporting routine insider transactions. The acquisition of performance shares is a positive indicator of executive alignment with company performance, while the sale for tax withholding is a standard, non-discretionary event.

Positives

• Acquisition of 4,304 common shares (2,152 immediately vested, 2,152 subject to 1-year vesting) through performance share achievement, indicating management's alignment with company performance.

Negatives

• Disposition of 805 shares for tax withholding purposes, which is a routine event upon vesting of equity awards and not a discretionary sale.

Future Outlook

2,152 performance shares acquired on December 22, 2025, are subject to an additional 1-year time vesting requirement.

Industry Context

This is a routine insider transaction filing (Form 4) for an executive at a publicly traded biotechnology company. Such filings are common and reflect executive compensation structures tied to performance and equity vesting.

Comparison to Industry Standards

• The acquisition of performance shares and subsequent sale for tax withholding are standard practices in executive compensation packages across various industries, including biotechnology. No specific comparable companies or projects are mentioned in this filing to allow for a detailed comparison.

Stakeholder Impact

• Shareholders: Minor impact. The transactions reflect routine executive compensation and ownership changes, aligning executive interests with shareholder value through performance-based awards.

Next Steps

• The 2,152 performance shares acquired on December 22, 2025, will be subject to a 1-year time vesting requirement.

Key Dates

Keywords

CYTOKINETICS, CYTK, Form 4, insider transaction, stock ownership, performance shares, executive compensation, Sung Lee, Chief Financial Officer